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Abstract: Staphylococcus aureus is a notorious pathogen that colonizes implants (orthopedic and breast
implants) and wounds with a vicious resistance to antibiotic therapy. Methicillin-resistant S. aureus
(MRSA) is a catastrophe mainly restricted to hospitals and emerged to community reservoirs, acquir-
ing resistance and forming biofilms. Treating biofilms is problematic except via implant removal or
wound debridement. Nanoparticles (NPs) and nanofibers could combat superbugs and biofilms and
rapidly diagnose MRSA. Nanotheranostics combine diagnostics and therapeutics into a single agent.
This comprehensive review is interpretative, utilizing mainly recent literature (since 2016) besides
the older remarkable studies sourced via Google Scholar and PubMed. We unravel the molecular
S. aureus resistance and complex biofilm. The diagnostic properties and detailed antibacterial and
antibiofilm NP mechanisms are elucidated in exciting stories. We highlight the challenges of bacterial
infections nanotheranostics. Finally, we discuss the literature and provide “three action appraisals”.
(i) The first appraisal consists of preventive actions (two wings), avoiding unnecessary hospital visits,
hand hygiene, and legislations against over-the-counter antibiotics as the general preventive wing.
Our second recommended preventive wing includes preventing the adverse side effects of the NPs
from resistance and toxicity by establishing standard testing procedures. These standard procedures
should provide breakpoints of bacteria’s susceptibility to NPs and a thorough toxicological exam-
ination of every single batch of synthesized NPs. (ii) The second appraisal includes theranostic
actions, using nanotheranostics to diagnose and treat MRSA, such as what we call “multifunctional
theranostic nanofibers. (iii) The third action appraisal consists of collaborative actions.
Keywords: methicillin-resistant S. aureus; biofilms; nanoparticles and nanofibers; theranostics;
mechanisms; appraisals
Highlights
• Staphylococcus aureus is a notorious resistant pathogen that emerged from hospitals to
communities, forming implant and wound biofilms.
• Nanotheranostics are “game-changers” combating this resistance and tolerant biofilms
via rapid diagnosis and multimodal therapeutic mechanisms.
• Appropriate stewardship considering our three action appraisals would beat the
global resistance and biofilm battle.
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1. Introduction
1.1. S. aureus and Resistance Mechanisms
Staphylococcus aureus is a substantial etiological agent of implant-associated infections [1–5],
skin or wound infections [6–10], nosocomial infections [11], sepsis, and death [12]. S. aureus is a
dire pathogen because of its potential to acquire resistance to antibiotics [10,13–15]. For
example, the acquisition of the mecA gene and production of a specific penicillin-binding
protein (PBP2a) fortify S. aureus, resisting penicillinase-resistant β-lactams (methicillin
or oxacillin) [16–19]. Apocalyptic outbreaks of methicillin-resistant S. aureus (MRSA)
have mainly been confined within hospital settings (hospital-acquired, HA-MRSA) and
to immunocompromised patients. Then, MRSA outbreaks emerged from hospitals to
community reservoirs. Healthy people could contract community-acquired MRSA (CA-
MRSA) [6,13,14,20,21], especially those of low socioeconomic status (lack of medical care,
crowding, poverty, and intravenous drug addiction) [22–24], and then die [21]. CA-MRSA
was reported to cause community-acquired pneumonia associated with influenza (during
the 2003–2004 influenza season) in the USA, eliciting severe illness and death [25]. CA-
MRSA strains are distinct from HA-MRSA in possessing a characteristic Staphylococcal
cassette chromosome mec (SCCmec) type IVa and some carrying Panton-Valentine leuko-
cidin (PVL) locus, producing PVL toxins [26,27]. PVL toxin is associated with skin and
soft-tissue infections, requiring increased surgical treatment, and rarely (i.e., in the USA),
it is associated with invasive pneumonia and poor prognosis [27,28]. The MRSA health
problem is augmented via the simple five factors or simple five Cs, as termed via the
Centers for Disease Control and Prevention (CDC) [29], facilitating MRSA transmission: (i)
Crowding, (ii) skin-to-skin Contact (with colonized or infected person), (iii) Compromised
integrity of skin, (iv) Contaminated fomites, and (v) Cleanliness deficiency. These factors
are common, with increased risk of CA-MRSA infections among military personnel and
day-care children [14,24]. The reported resistance of MRSA to vancomycin worsens the
bacterial antibiotic resistance scenario [30–35]. This worse situation is because vancomycin
is the bedrock of last-resort antibiotics treating notorious MRSA infections [36–38], be-
sides linezolid and daptomycin [31]. If bacterial antibiotic resistance is currently a global
bottleneck challenge, then the critical question here is: What are the future consequences
of such bacterial antibiotic resistance? A direct answer is to return to the point of the
pre-penicillin era, lack of new antibiotic classes, and the disengagement of pharmaceutical
companies from the antibiotic research pipeline owing to the high economic burden of
developing novel antibiotics and executing clinical trials [39–41]. In terms of numbers,
by 2050, 10 million people would be expected to die every year globally [42,43], and more
than 1.2 trillion USD would be added to world health care costs every year [44,45]. A
cumulative global cost of up to 100 trillion USD would be expected if bacterial antibiotic
resistance was not tackled [43].
What are the mechanisms behind the ruthless antibiotic resistance of bacteria? Evi-
dence suggests that the essential mechanisms facilitating intrinsic (i.e., inherent or innate)
bacterial antibiotic resistance are (i) alterations of bacterial membrane permeability and
deoxyribonucleic acid (DNA), (ii) multidrug efflux pumps, and (iii) the inactivation of
enzymes [46–48]. On the other hand, acquired bacterial antibiotic resistance is facilitated
via chromosomal mutations or the acquisition of antibiotic resistance genes (horizontal
gene transfer between bacteria) mediated by mobile genetic elements such as plasmids and
transposons [4,49,50]. Adaptive antibiotic resistance is a transient alteration of expression
of bacterial genes or their cognate proteins fostered by previous bacterial exposure to either
non-lethal antibiotic concentration or successive high antibiotic doses and environmental
stressors (e.g., pH, temperature, and limitation of oxygen or nutrients) [51,52].
1.2. S. aureus in Biofilms and Resistance and Tolerance Mechanisms
What inflames the bacterial antibiotic resistance or tolerance puzzle is the existence of
biofilms in most chronic bacterial infections (i.e., medical implant- and wound-associated
infections) [51,53–56]. S. aureus is a key biofilm producer [1,57–59], utilizing a system of
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cell-to-cell communication called quorum sensing (QS). The chromosomal locus regulating
QS in S. aureus is called accessory gene regulator (agr), encoding the production of a diffu-
sive distinct autoinducer molecule (indicating local cell density). This agr quorum-sensing
system plays a pivotal role in the pathogenicity of S. aureus [6,60,61] via coordinating
the architecture, bacterial growth rates, species interactions, and virulence factors (toxin
production and exoenzymes) of biofilms [6,56,62]. Biofilms are sessile microbial cell commu-
nities embedded in an extracellular polymeric substance, forming a matrix and exhibiting
a sophisticated altered phenotype concerning bacterial physiology, metabolism, and gene
transcription [8,63–66]. The extracellular polymeric substance (EPS) matrix adheres to
periprosthetic tissue and surfaces of medical implants [1,53,63,65,67] and wounds [68,69]
or enables cell–cell adhesion and aggregation, forming mobile biofilms (flocs) without
substrate [56,70,71], as shown in Figure 1. The matrix is composed of bacterial secreted
polymers, e.g., exopolysaccharides, lipids, proteins, and extracellular deoxyribonucleic acid
(e-DNA), arming bacteria with intricate three-dimensional (3D) structure and excessive re-
sistance or tolerance against antibiotics. The e-DNA could prompt the expression of resistance
genes and the horizontal gene transfer between bacterial cells within biofilms [1,51,72–74].
With the advent of emergent resistant bacteria and their tolerant biofilms, there is a need
to explicitly elaborate on the difference between ‘resistance’ and ‘tolerance’. The term
‘resistance’ refers to a permanent genetic change in bacteria that could be acquired through
point mutation or horizontal gene transfer. As a result of this permanent genetic alteration,
the resistance continues with bacterial cells in biofilms and their dispersed planktonic cells.
Moreover, resistance paves the way for bacteria not only to survive in the presence of
drugs but also to replicate and is tied to the minimum inhibitory concentration (MIC), as a
higher MIC confers a higher resistance. Comparatively, ‘tolerance’ describes a transient
characteristic feature enabling bacterial cells’ survival in the presence of antibiotics (e.g., the
complex lag phase of bacterial growth as a transient non-replicative evolvable phenotype
tolerates antibiotics [75]) without an increase in the MIC. Tolerance is mostly linked to
bacterial cells growing in the biofilm phenotype. Therefore, tolerance could be lost when
biofilms are dispersed into their planktonic cells [51,56,70,71,73,76].
The biofilm matrix structure contains open fluid channels, resembling the circula-
tory system and delivering nutrients to deeply embedded bacterial cells [62,63,77]. The
matrix also provides local heterogeneous, compartmentalized chemical and physical mi-
croenvironments that resemble the heterogenous compartmentalized tumor ECM [70,78].
The biofilm matrix structures are seen in Figure 2. Biofilm formation could be classified
into four consecutive steps (as formed in Figure 1 on the hip implant): (i) initial bacterial
adhesion to tissue or surfaces (starting as reversible adhesion; then, cells undergo species-
specific behavior and secrete exopolysaccharides, changing to irreversible adhesion) via
cell-surface-associated adhesins. (ii) Initial biofilm formation, where microcolonies and
fluid channel architecture are formed within the produced EPS. (iii) Biofilm maturation,
where EPS develops into a 3D scaffold, facilitating the formation of heterogeneous chem-
ical and physical microenvironments. (iv) Dispersal, where a detachment of some cells
from biofilms into planktonic cells, colonizing new tissue or surfaces [1,51,62,68,70,77], or
cells tolerate antibiotics more than the planktonic cells [79]. Biofilms usually comprise
multispecies bacterial communities (and other microorganisms), making it implausible that
a single antibiotic quenches these diverse bacterial communities [55,56,72,80]. These multi-
species bacterial communities are encased within an envelope (EPS matrix) and interact
mostly cooperatively within the matrix and with cells of other organisms and the environ-
ment [71]. Bacterial subpopulations within the biofilm could suffer starvation or switch
phenotypically after stress exposure to antibiotic treatment into slow- or non-growing
persisters (persister cells). These persisters tolerate antibiotics [46,54,67,70,71,73,79,81,82]
and elicit recurrent infections [53,83], as seen in Figure 2. Interestingly, persisters could also
present in small proportions of non-stressed populations as an insurance mechanism to
escape lethal stressors’ attack. This insurance mechanism stems from the fact that metaboli-
cally inactive non-growing cells demonstrate enhanced tolerance to antibiotics compared
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with their replicating counterparts [83–85]. Despite the stochastic development of persis-
ters, the tendency to form them remains a genetically controlled trait [82,83,85]. This trait
is controlled via HipBA (the hip is a high persister mutant), constituting a toxin–antitoxin
(TA) locus in the workhorse model organism, Escherichia coli. Throughout normal bacte-
rial replication, protein toxins are bound to their antitoxins (protein or RNA), inhibiting
toxin activity. Throughout the persister scenario, toxins are liberated, inhibiting DNA
replication and mRNA cleavage that inhibits global bacterial protein transcription and
translation [85,86]. The escalating question here is: would the same TA module signal-
ing pathway control the development of persisters in S. aureus? Consistent with the TA
module signaling pathway in E. coli, Corrigan et al. [87] have also found that guanosine
pentaphosphate, (p)ppGpp, was the pacemaker driving the formation of tolerant persisters
in S. aureus via inhibiting GTPases. The inhibition of GTPases reduces the growth and
amount of mature 70S ribosomes of cells and increases the antibiotic tolerance of cells.
Surprisingly, Conlon et al. [88] noted that the deletion of TA modules (i.e., no increased
production of (p)ppGpp) did not affect the level of the produced persisters in S. aureus.
The unexpected finding was that persisters emanated from a stochastic process of bacterial
entrance into the stationary phase and associated with a decrease in the intracellular level
of adenosine triphosphate, losing energy and developing antibiotic tolerance. Persisters
also have the following hallmark features. (i) The biphasic killing curve is a heteroge-
nous non-uniform killing rate of bacteria that describes the rapid killing of most bacterial
within 25 min. The remaining cells are killed after a longer time, up to 6 h [76,82,85].
(ii) The production of susceptible progeny cells to antibiotics is similar to their progeni-
tors if they resume growth without antibiotics [76,79,89,90], as seen in Figure 2. (iii) The
third hallmark feature is the heterogeneity of persisters exemplified via their bet-hedging
stochastic formation. The concept ‘bet-hedging’ is an evolutionary strategy, depending
on the phenotypic heterogeneity that facilitates the survival and tolerance of persisters
against hefty stressful conditions [83]. In light of the biofilm broader view, biofilms possess
less susceptibility to antibacterial agents and infected hosts’ immune systems than their
planktonic (free-living) counterparts [1,53,55,56,62,91]. Biofilms are mostly untreatable
except by surgical removal of the infected medical implant [53,64,65,67,80] or sharp de-
bridement of wounds [55,56,68,69]. There remains little agreement on the exact resistance
or tolerance mechanisms of biofilms against antibacterial agents [64,91]. There are several
reasons why biofilms have such a heightened resistance or tolerance against antibacterial
agents: (i) the slow and impaired diffusional penetration of antibacterial agents across the
physical barrier (the matrix and layers of cells) of the biofilms [1,64,65,67,71]. This barrier
is also a protective hurdle against the invasion of infected hosts’ immune macrophages into
biofilms [92]; (ii) the existence of persister cells and small-colony variants (SCVs, character-
ized by slow growth, reduced metabolism, less motility, and associated with environmental
stress, such as antibiotic treatment causing their phenotypic or genetic changes) that are
tolerant and resistant to antibiotics, respectively [1,5,70,71,93–95]; (iii) stress-adaptive re-
sponses of bacterial cells in the biofilm and the induction of rpoS (RNA polymerase sigma
factor)-mediated stress cause their slow growth and protection against environmental stres-
sors and chemical agents [1,64,96]; (iv) heterogeneity of the chemical microenvironment
(e.g., oxygen levels and pH gradients, ranging from <5.5 to ≈6.5 [97,98]) within the biofilm
antagonize antibacterial agents [1,54,56,65,94]; (v) upregulation of resistance-associated
genes in biofilms [1,56]; (vi) uptake of resistance genes through horizontal gene transfer
in biofilms, i.e., plasmid conjugation and mobilization [58,71]; and (vii) the multispecies
bacterial communities within the biofilm consortia [56,70].




Figure 1. Nanotheranostics diagnose via visual detection, or fluorescence microscope, or monitor-
ing. Nanotheranostics treat via, e.g., photothermal therapy (PTT) with gold nanoparticles (NPs) 
(GNPs) inducing thermal damage. Photodynamic therapy (PDT) releasing reactive oxygen species 
(ROS). Physicochemical properties of NPs as metal ions release (MIR), their cargo (e.g., antibiotics), 
and physical disruption by nanoknives or structurally nanoengineered antimicrobial peptide poly-
mers (SNAPPs). “Multifunctional theranostic nanofibers” could be directly electrospun on a dia-
betic foot ulcer. Staphylococcus aureus associated implant (hip or breast) and wound infections. Steps 
of S. aureus biofilm formation on the hip implant are initial adhesion, microcolonies formation 
within an extracellular polymeric substance (EPS), biofilm maturation (3D EPS), and dispersion of 
planktonic cells recolonizing the implant. Surgical site infection (SSI) following breast construction 
could cause breast implant loss. S. aureus cells could adhere to each other, forming mobile biofilm 
flocs. Nanotheranostics perform diagnosis and therapy of S. aureus. 
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Figure 2. The lifestyle of Staphylococcus aureus biofilms (colonizing the hip implant). The biofilms 
are multispecies aggregates of cells, secreting a protective extracellular polymeric substance (EPS) 
contains open fluid channels, resembling a circulatory system. The EPS has heterogeneous compart-
mentalized microenvironments, resembling tumors, with different oxygen levels (aerobes, ferment-
ers, anaerobes) and pH gradients < 6.5. Bacterial subpopulations of small-colony variants (SCVs, 
tolerant and resistant to antibiotics) and persisters are formed within biofilms. Persisters are antibi-
otic tolerant, eliciting recurrent infections, and producing progeny susceptible to antibiotics when 
resuming growth with no antibiotics. The biofilm EPS and embedded layers of cells constitute a 
physical barrier, impairing the diffusional penetration of antibiotics and invasion of immune mac-
rophages into biofilms. 
Figure 2. The lifestyle of Staphylococcus aureus biofilms (colonizing the hip implant). The biofilms
are multispecies aggregates of cells, secreting a protective extracellular polymeric substance (EPS)
contains open fluid channels, resembling a circulatory system. The EPS has heterogeneous co part-
mentalized microenvironments, resembling tumors, with different oxygen levels (aerobes, fermenters,
anaerobes) and pH gradients < 6.5. Bacterial subpopulations of small-colony variants (SCVs, tolerant
and resistant to antibiotics) and persisters are formed within biofilms. Persisters are antibiotic toler-
ant, eliciting recurrent infections, and producing progeny susceptible to antibiotics when resuming
growth with no antibiotics. The biofilm EPS and embedded layers of cells constitute a physical
barrier, impairing the diffusional penetration of antibiotics and invasion of immune macrophages
into biofilms.
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1.3. Nanotechnology Offers Diagnostic and Antibacterial and Antibiofilm Properties
There is a robust demand to research novel antibacterial agents that defeat the global
antibiotic resistance crisis to avert returning to the pre-penicillin era [46] or entering the
post-antibiotic era, where common bacterial infections could kill [99,100]. This demand
includes novel multi-targeted antibacterial agents effective against multi-(bacterial species
and faceted properties) of biofilms [53,59,70,80]. Nanoparticles (NPs) could combat super-
bugs due to their unique physicochemical properties, generating heightened therapeutic
effects against planktonic cells and biofilms [74,101]. The fundamental three antibacterial
mechanisms of NPs are central to (i) induction of oxidative stress through the production
of reactive oxygen species (ROS) that disrupt bacterial membranes, inactivate essential
proteins and enzymes, and express oxidative proteins. (ii) Release of metal ions, interact-
ing with functional groups (e.g., phosphates, sulfhydryl, carboxyl, amino) of DNA and
proteins and disrupting their physiological functions. (iii) Induction of non-oxidative stress
through the interaction of NPs with bacterial cell membranes, resulting in cytoplasmic
leakage [47,74]. The main antibacterial prowess of NPs is that these antibacterial mecha-
nisms could coincide, decreasing the probability of bacteria to develop resistance because
multiple simultaneous bacterial gene mutations would be required [47,101,102]. Therefore,
antibacterial NPs could achieve the outstanding concept of ‘resistance-resistant’, where
multi-target bacterial inhibition occurs, and NPs become more resistant to resistance de-
velopment. This concept would be a technological leapfrog rather than discovering novel
antibiotics, which could be a daunting process and an economic burden [103]. Considering
the pioneering properties of antibacterial NPs, how could these properties have a pivotal
role in inhibiting or eradicating the biofilm dilemma? To date, the fundamental answer is
the size of NPs (5 to 200 nm) that allow their penetration through the fluid channels (10 nm
to few micrometers) of biofilms [74]. Even though more than a hundred years have elapsed
since Paul Ehrlich was awarded the Nobel Prize, his concept of developing “magic bullets”
still dominates a significant area of interest within the field of pharmaceuticals [104,105].
This domination stems from the promising therapeutic efficacies and the minimal draw-
backs of these magic bullets because they specifically target certain bacteria, killing them
with a few harmful side effects on other body tissues [105]. By contrast, biofilm infections
are similar to a fortress of multispecies bacterial communities and multifaceted physical
and biological properties, providing shelter against single “magic bullet” strategies [70].
In terms of targeted drug delivery, NPs could also be used as potential drug carriers,
facilitating targeted delivery and the controlled release of drugs [47,102].
If NPs could combat the bacterial resistance and biofilm dilemma, then how would
nanotheranostics potentially revolutionize medicine? It is necessary here to first clarify
what is meant by theranostics. The term “theranostics” is commonly referred to as a com-
bination of diagnostic and therapeutic properties into a single component [106,107] and
emerging as a powerful platform toward personalized medicine [106,108]. Speaking on the
aimed personalized medicine, it extends beyond the warm, caring manner to patients [109]
and the traditional idea of one drug fitting all patients toward administering the specific
drug to the right patient at the right time [108]. The availability of a single agent for diag-
nosis and treatment is at the heart of challenges facing the transfer of theranostics into the
clinical field; however, nanotechnology can cross this challenge by entangling diagnostics
and therapeutic agents [108]. Diving more specifically into the theranostic nanomedicine,
it encompasses the NPs tagged by labels or possessing intrinsic physicochemical properties
that can diagnose the disease and induce treatment themselves or through their carried
cargo (e.g., chemo-, radio- or gene therapeutics or combinations of them) [110,111]. Tagging
bacterial-derived antigens with NPs ameliorates the signals detected from the targeted
specific binding of even low bacterial concentration and forms a thorough diagnostic
probe [112]. The early diagnosis and treatment of diseases are priceless because at the
earliest stage, the diseases are curable or at the least treatable [107]. Therefore, theranostics
facilitate superior control of the diseases [111], increase therapeutic efficacy, and avoid the
drawbacks [108,111].
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In contrast to extensive theranostic research on different cancer types, there is much
less information about theranostic effects against bacterial infections and their biofilms,
which also pose a growing public health concern worldwide. However, antibacterial nan-
otheranostics can play a pivotal role in tackling this bacterial antibiotic resistance quandary
and their biofilms via detecting (sensing) the presence of bacterial infection and conse-
quently facilitating treatment [111]. Nanotheranostics could provide prowess rapid and
accurate bacterial identification, helping to cross the hurdle of a low number of pathogens
at early infectious stages [112] and the long (i.e., two days) traditional antibacterial sus-
ceptibility tests. Consequently, nanotheranostics could achieve higher success treatment
rates [108,112]. Previous review articles [106–108,110] focusing on understanding the pow-
erful impact of developing nanotheranostics for chemotherapy and different biological
applications do exist. However, the exact nanoparticles’ antibacterial working mechanisms
are still not known. This comprehensive review generates fresh insights into the detailed
antibacterial and antibiofilm therapeutic mechanisms of nanotheranostics. We elucidate
such mechanisms after providing a deeper understanding of S. aureus resistance and biofilm
(lifestyle, mysteries surrounding it, and its resistance and tolerance) in a grasping narrative
context supported by our constructed informative, artistic figures. Therefore, this review
makes several significant contributions to the more in-depth understanding of the emergent
resistant bacterial infections, specifically MRSA and their tolerant biofilms associated with
implants (orthopedic and breast) and wounds. The present review explores the critical
roles of different antibacterial nanotheranostics in curbing bacterial resistance and biofilm
dilemmas. We provide essential insights on the challenges dampening the progress of such
antibacterial nanotheranostics that are usually overlooked in studies. Ultimately, we reflect
on our critical perspectives, highlight research gaps, and answer the big question in this
field: How can we solve S. aureus resistance and its tolerant biofilms?
2. Implant-Associated Infections
One of the major problems ensuing orthopedic implant surgery is a bacterial in-
fection, resulting in osteomyelitis and prosthetic joint-associated infections (PJIs) [113].
Gentamicin is an aminoglycoside antibiotic [114] with potent bactericidal activity against
Gram-negative bacteria and the Gram-positive S. aureus, which is the most vicious bacterial
infection associated with osteomyelitis and PJIs [115]. Although gentamicin is thermally
stable [113,116], its main disadvantages are its nephrotoxicity, ototoxicity [114], and poor
penetration into deep bone surgery sites. Therefore, local treatment would attain the
stunning advantages of gentamicin and avoid its disadvantages [113,116]. Multimodal
treatment could outpace orthopedic implant-associated infections. This multimodal treat-
ment comprises systemic antibiotic administration, local slow-releasing gentamicin-loaded
beads, and the debridement of necrotic and infected tissue [116–118]. This local gentam-
icin therapy crucially supports systemic antibiotic administration, preventing orthopedic
implant-associated infections [119], and it remains important to achieve concentrations
that exceed the MIC of infecting pathogens [118]. Regarding debridement, the resulting
bone defects could be either filled with autologous (bone or muscle) tissue or with im-
plants (beads), such as polymethylmethacrylate (PMMA) [113]. PMMA beads loaded with
gentamicin have been clinically applied in practice over the past 45 years, incorporating
gentamicin between chains during the exothermic polymerization process [113,116,118].
Gentamicin release from PMMA beads is a diffusion phenomenon classified into two
phases. First, an initial burst release lasts from minutes to hours following implantation,
where the surface gentamicin dissolves from PMMA into body fluids. Second, a prolonged,
slower sustained release lasts from several days to years, where water-soluble gentamicin
diffuses from the PMMA (hydrophilic material attracting water molecules) following the
in-depth penetration of water containing body fluids [118,120]. The main issue pertinent to
PMMA beads is the necessity for secondary surgery to remove the non-absorbable beads.
The beads could also act as a surface for the colonization of secondary bacterial biofilms
after releasing gentamicin [116] and specifically if the released concentration is insufficient
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(sub-lethal concentration) [118]. Sub-lethal antibiotic concentrations drive the formation of
S. aureus biofilms and offer a chance for biofilm cells to switch into persisters [79]. Several
other attempts have been made to avoid the drawbacks of gentamicin and PMMA beads,
such as the attempt of Moghaddam et al. [121] using Expert Tibia Nail (ETN) PROtect™
coated by a biodegradable gentamicin-laden polymer, which does not release gentamicin
into the circulation, avoiding its systemic drawbacks and preventing osteomyelitis [121].
However, if biofilms are formed, the shortage of oxygen and nutrients within them makes
bacteria tend to shuffle into anaerobic metabolism, increasing the acid production that
reduces the activity of gentamicin [113,114]. Moreover, the slow, sustained gentamicin
release from the beads incurs the development of SCVs. S. aureus SCVs were isolated from
four patients with a history of previous treatment with gentamicin beads. The treatment
strategies for patients with SCVs end in failure, even though the administered antibiotics
were effective in vitro against S. aureus progenitors (i.e., MICs of gentamicin ramped up
to 32-fold higher for SCVs) and recurrent infections. Conversely, patients with no SCVs
suffered no recurrent infections [117]. Tackling the puzzle of SCVs, two S. aureus (wild-type
and SCV) strains were recovered from a patient with an implanted knee suffering PJI
during the acute and recurrent phases. The resistance of S. aureus SCVs overweighs the
resistance of the wild-type strain via multi-complex protective approaches against the host
inflammatory and oxidative responses. Examples of such protective approaches of SCVs are
(i) possessing a stringent response characterized by an inhibition of DNA replication and
post-transcriptional regulation via decreased ribosomal assembly, inhibiting bacterial cell
growth. (ii) Virulent expression of toxins, including phenol soluble modulins (PSM, causing
both the evasion of S. aureus to host neutrophils and indolence within host osteoblasts),
alpha- and delta-hemolysins, and the agr locus. (iii) Upregulation of genes detoxifying
the host oxidative stress response. (iv) Downregulation of genes involved in the cell wall
regulon vraRS, orchestrating antibiotic resistance and switching SCVs from acute to chronic
infections [5]. A more dramatic PJI was reported in a patient with an implanted right hip
prosthesis, where his left hip was previously replaced with 60 gentamicin-impregnated
cement beads. His right hip prothesis was loosened and, consequently, replaced. The
dramatic scene was the isolation of gentamicin-resistant Staphylococcal strain from the hip
prosthesis. Then, the authors questioned the usefulness of using gentamicin-impregnated
cement beads. Did the used beads help the patient or stimulate the development of the
gentamicin-resistant Staphylococcus strain [122]? The suspicions about the efficacy of ad-
ministrating gentamicin-releasing cement were summarized as such cement adversely
contributes to the development of gentamicin resistance because of the insufficient sub-
lethal released concentrations [122,123]. Another problem that has recently been addressed
regarding local gentamicin therapy following knee implant was the ‘hidden’ gentamicin
allergy, causing pain and swelling of the knee, and allergic contact dermatitis [124].
The human breast contains endogenous flora originated from the nipple ducts, similar
to that of the healthy skin [3]. Staphylococcal skin flora are commensally resided and com-
monly cultured from surgical sites following breast reconstruction (BR) [20]. The patient’s
skin is the predominant source of infection at the time of surgery. Surgical site infections
(SSIs) could worsen this infection scenario, provoking breast implants’ loss (as displayed
in Figure 1) and costing healthcare systems [125]. Multidrug-resistant bacteria, causing
nosocomial infections, are the most common implant-associated infections [1]. Postopera-
tive infections have existed as a challenging complication following BR. Surgical procedure
(i.e., surgical environment, contaminated saline, contaminated implant during surgery)
and the underlying clinical condition of the patient are the main contributing factors for
breast implant-associated infections [3]. Regarding orthopedic implants, bacterial antibiotic
resistance made routine surgical procedures, such as hip and knee replacements, a looming
challenge because of a foreseeable risk of contracting a life-threatening untreatable bacterial
infection [4,103]. However, the infection rates in orthopedic implants (an incidence rate of
1.5% [126]) remain lower than in breast implants, which have an incidence rate ranging
widely between 1% and up to 35% [127], resulting in breast explantation and making it
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compelling to adopt a series of precautions at BR to reduce such a high infection rate.
The assessment of 121 breast implant procedures from seven breast units operated by
22 surgeons revealed inconsistent prophylactic precautions. What stood consistent was
the MRSA screening and prophylactic perioperative administration of antibiotics. The
authors concluded that a breast implant checklist for infection prevention could be a better
practice [128]. Barr et al. [125] have set a “Theatre Implant Checklist” to prevent SSIs in BR,
including four main points. (i) Pre-operation, has MRSA screening been performed and
treated if positive? (ii) Upon surgery induction, there is a series of checkpoints as has the
patient received prophylactic antibiotics? Has a conductive warming blanket been placed?
Have no entry signs been put on doors, and laminar flows been operated? (iii) Upon
implantation, the following should be checked. Have the implant pockets been washed,
and the surgeons changed their outer gloves before implant handling? (iv) Post-operation,
have postoperative antibiotics been prescribed? Although Hart et al. [20] found a low
incidence of MRSA colonization (<5%) postoperatively following BR, they pointed out an
association between postoperative MRSA colonization and the delayed wound healing.
This drawn association arose because MRSA carriers showed a higher incidence of major
complications as postoperative SSI followed by delayed wound healing. This delayed
wound healing was explained by MRSA colonization’s natural sequelae to contaminate
wounds and subsequently impair healing. More recently, Agochukwu et al. [129] reported
the most extended case of a late bilateral breast MRSA infection after 19 years of breast
augmentation in a 42-year-old woman. The case had a history of intravenous drug abuse,
causing the hematogenous spread of the transient bacteremia to end with concurrent breast
and sternal infections. The adopted treatment regime was explantation and long-term
intravenous vancomycin.
3. Wound-Associated Infections
The skin stays the largest and most exposed human body organ [6,8,130,131], shield-
ing the body against the penetration of pathogenic bacteria [131–133]. There are two
primary components of the skin: the outermost epidermis (epithelial component) and
the underlying dermis (connective component) [6,131,133,134]. Skin epidermis includes
the interfollicular epidermis, hair follicles, and several stratified layers of differentiated
keratinocytes, melanocytes, and Langerhans cells (dendritic immune cells) [131,134,135].
These layers of differentiated keratinocytes are mainly responsible for the physical barrier
function of the epidermis [133,134]. Skin dermis includes innate cells (i.e., macrophages,
dendritic cells, and mast cells), innate lymphoid cells, and many lymphocytes, which
mediate the immunological function of skin, including phagocytosis or killing of invading
bacteria that breach the skin [134]. Moreover, preventing pathogenic bacteria from pen-
etrating through and dwelling epithelial surfaces could be a collaboration of two other
approaches. First, the non-specific immunity of skin (acidic pH, lipid density, and scarce
nutrients) orchestrates a harsh environment against pathogen invasion. Second, the com-
petition between the commensal microbes colonizing cutaneous surfaces and invading
bacterial pathogens is achieved via secreting novel natural products [6,130], highlighting
this concept as “colonization resistance” [8,62,134]. On the other hand, all open wounds
lack a protective skin barrier and contain endogenous (skin flora of patient) or exogenous
bacteria, which are initially killed by the patient’s immune system. However, suppose the
bacteria are attached to the wound surface and proliferated to a mature biofilm, resulting
in a biofilm-infected wound [62]. In that case, that remains the most common barrier
hindering wound healing [8,68].
Even though inflammatory cells (such as macrophages) at the wound site incur tissue
repair and regeneration, dysregulation of the inflammatory response can plausibly occur,
converting the wound into chronic [136]. Chronic wounds referred to non-healing wounds
from 30 days or more [68,137]. Notable examples of chronic wounds are diabetic foot
ulcers, pressure injuries, venous stasis ulcers, and ischemic ulcers [68,137–139]. Chronic
wounds also fuel the formation of biofilms because necrotic tissue and debris are niches for
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bacterial attachment. Compared to acute wounds, chronic wounds are more vulnerable
to infection because of compromised immunity of patients [55,68], reduced susceptibility
to antibiotics and greater activation of inflammatory responses [56]. Biofilms in chronic
wounds are also a culprit for “hijacking” the patient’s immune response [138]. This
hijacking is facilitated via expressing superantigens (e.g., enterotoxins and toxic shock
syndrome toxin-1 of S. aureus), enabling a final release of pro-inflammatory cytokines from
T lymphocytes [138,140] and so manipulating the immune response of the patient to be
in a perpetual state of hyper-inflammation. In this hyper-inflammation state, the patient
cannot conquer biofilms [138]. A previous study [137] has established a clear-cut more
prevalence of biofilms in chronic wounds (60%) than in acute wounds (only 6%). To further
perplex biofilms in chronic wounds, multispecies bacterial communities are predominant in
biofilms in chronic wounds [68], and limited oxygen in deeper embedded cells of biofilms
orchestrates the proliferation of anaerobes [56]. Previous studies have confirmed that
S. aureus is the most prevalent universal bacterial insult to chronic wounds [37,141–143].
Sievert et al. [144] have identified a case of seven patients infected with vancomycin-
resistant S. aureus (VRSA) in the USA. All infected patients embraced chronic underlying
conditions, such as chronic skin ulcers and diabetes, a history of infection with MRSA and
vancomycin-resistant enterococci (VRE), and a previous treatment with vancomycin. The
authors suggested that VRE transferred the vanA gene to S. aureus via plasmid conjugation.
This vanA gene transfer was proven [15] in studies that isolated VRSA from a polymicrobial
biofilm colonizing indwelling nephrostomy tube, where VRE (Enterococcus faecium) donated
the non-integrated vanA gene to MRSA. Neopane et al. [9] demonstrated that S. aureus
isolated from wounds of hospitalized patients possess a spectacular ability to form biofilms
and multidrug resistance (86.7% of isolates), where 43.3% of S. aureus in biofilms were
identified as MRSA. It has also conclusively been shown that [145] S. aureus in biofilms halt
wound healing via delaying wound re-epithelialization.
4. Antibacterial Nanotheranostics
Investigators have recently examined the properties of nanotheranostics, including
antibacterial agents such as antibiotics, NPs, antibacterial peptides or polymers (i.e., star-
shaped polymers), photodynamic therapy (PDT), and photothermal therapy (PTT) [111],
as shown in Figure 1. PDT is generally understood to mean a kind of therapy involving the
targeted delivery of a photosensitizer (PS) to the infected site and being irradiated with
light of a specific wavelength, consequently activating the PS to produce ROS damage the
infected cells. PTT refers to administering a probe, absorbing light, and transforming it
into heat that destructs the infected tissue [111].
4.1. Theranostic Nanoparticles (NPs) and Nanofibers
Nobel metal NPs, such as silver (Ag), gold, and platinum, have long been used as
therapeutic antibacterial agents [102,112]. Gold NPs (GNPs) could specifically be tied with
therapeutic drug delivery and diagnostic applications because of their unique properties
(e.g., facile preparation, surface functionalities, tunable core size, photothermal, and surface
plasmon-related optoelectronic properties, inertness, and biocompatibility) [112]. Semi-
conducting NPs (defined as quantum dots, QDs), such as zinc sulfide, cadmium sulfide,
and zinc oxide, have become vital tools in the diagnostic bioimaging and therapeutic drug
delivery because of their size- and shape-dependent optoelectronic properties and high sur-
face area to volume ratios [112,146]. Mesoporous silica NPs (MSNs) provide massive thrust
to the area of antibacterial drug delivery, loading up to 10-fold more drug than non-porous
silica NPs [74]. The available tuning of the core size, surface functionalities, and structural
features of MSNs (e.g., high surface areas and tunable nanometer-scale pore sizes) make
them a groundbreaking system that optimizes multifunctional therapeutic controlled drug
release and diagnostic imaging modalities [102,147]. MSNs could palpably deliver the
antibiotic cargo in a targeted manner, achieving the required antibiotic concentration at the
infected tissue and reducing the drawbacks of systemic antibiotics [102,148].
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4.1.1. Nanoparticle-Mediated Diagnosis of S. aureus
Aptamers are small artificial single-stranded nucleotides (10 to 100) that bode well
in the efficient binding and detection of bacterial targets. In NP-mediated colorimetric
aptasensors, NPs could assist the capturing aptamer (the bioreceptor detects and binds
the target) and participate in signal conversion (by transducer or probe) [149]. Chang
et al. [150] developed an easy and low-cost method to accurately detect S. aureus using
aptamer-conjugated GNPs (60 nm) followed by a bead-based amplification. They used
a light scattering-sensing system to detect the amplified GNPs, detecting single bacterial
cells within 1.5 h. Wang et al. [151] also developed an easy, sensitive, and selective colori-
metric method for the detection of S. aureus. They combined copper-based metal–organic
framework (Cu-MOF) NPs (size of 550 nm) modified with S. aureus aptamer and Fe3O4
modified with S. aureus aptamer. The method is based on the peroxidase-like activity of
Cu-MOF NPs catalyzing 3,3′,5,5′-tetramethylbenzidine in the presence of H2O2, producing
a yellow color. In the presence of S. aureus, the aptamer-modified Cu-MOF and Fe3O4 NPs
specifically bind the surface of S. aureus cells. Following magnetic separation, Cu-MOF NPs
bound to bacterial cells would be removed from the supernatant, decreasing the number
of Cu-MOF NPs in the supernatant and so fading the yellow color with the increased
concentration of S. aureus (as depicted in Figure 3).
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4.1.2. Nanoparticle-Mediated Therapeutic Antibacterial and Antibiofilm Actions
This review pioneers our understanding of the mechanisms behind the antibacterial
therapeutic effects of NPs. We will begin with the mechanistic story and address a series of
confusing questions to elaborate on the different mechanisms as delineated in Figure 4.
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tively. Ag NPs or Ag+ inhibit the electron transport chain, collapsing respiration. Gentamicin in drug-delivery systems 
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tracellular polymeric substance (EPS) of mature biofilms. The antibacterial mechanisms of NPs also kill bacterial cells in 
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Assuming that Ag NPs or NPs, in general, are similar to therapeutic gunshots, once
the shot hits and interacts with the treated bacterial cell membranes, it forms “pits” that
damage the membranes, increasing the permeability of bacterial membranes and killing
the bacteria [152]. Then, the Ag NP shots may inactivate the bacterial respiratory chain dehy-
drogenases, inhibiting respiration [153], and form ROS, damaging the membranes [154,155]
(more specific roles of ROS are explained below in Section 5.2. PDT). Factors that affect
the bacterial killing efficiency of Ag NP shots remain unclear. The size of the Ag NPs is a
fundamental factor. Smaller Ag shots (1 to 10 nm) kill bacteria more efficiently than larger
shots [156–158]. These small nanoshots have large surface areas that allow larger contact
areas with the bacterial cells, killing them [157,159,160].
The immobilization of Ag NP shots on substrates (silica) allows more contact-mode
interactions between Ag shots and cells because it inhibits the sequestration of shots within
the bacterial cells [161]. Smaller Ag NP shots with high surface areas have higher oxide
contents [162]. The oxidized Ag NPs release more Ag+ ions [163]. Ag+ ions (as such
or released from Ag NPs) are soft acids motivated to interact with soft bases containing
sulfur and phosphorous. The interaction of Ag+ ions with sulfur-containing proteins in
bacterial cell walls and thiol groups of bacterial enzymes and proteins inactivates them,
damaging bacterial membranes. The interaction of Ag+ ions with phosphorus parts of
DNA prevents bacterial replication [164,165]. Ag+ ions also inhibit the bacterial electron
transport chain (which is membrane-bound) via facilitating the oxidation of respiratory
membrane-bound enzymes (flavoprotein and cytochrome b1), eventually collapsing bacterial
respiration [166,167]. From the mechanisms above, we notice substantial differences and
cannot deny the similarities between the antibacterial actions of Ag NPs and Ag+ ions. Can
we attribute the antibacterial mechanisms of Ag NP shots to Ag+ ions? Our previous study
has pointed toward the extensive different mechanistic antibacterial actions of Ag NPs
and Ag+ ions and concluded that Ag NP shots mainly damage the bacterial membranes,
whereas Ag+ ions mainly target bacterial DNA [158]. A more recent review was dedicated
to referring to these substantial differences and similarities between the antibacterial
mechanisms of Ag NP shots and Ag+ ions. The review extended to shape the formula that
not only are the antibacterial mechanisms different, but the bacterial resistance mechanisms
against Ag NP shots and Ag+ ions would also be different [162].
Would there be antibacterial properties related to the shape of NP shots? Van Dong et al. [168]
have highlighted the role of geometric structures (sharp edges and vertices) of triangular
silver nanoprisms (broad size range of 25 to 400 nm) in the more prominent antibacterial
effects compared with the spherical NPs (even with smaller average sizes of 21 nm). The
sharp vertices of Ag nanoprisms disrupt the bacterial membranes, easing the penetration of
more Ag prisms into the bacterial cells. In a leading article devoted to stress on the shape-
dependent antibacterial effects of Ag NPs [160], truncated triangular silver nanoplates with
{111} lattice planes showed the best antibacterial effects against E. coli among other shapes
of Ag NPs (spheres and rods) and even Ag+ ions. The authors also mentioned the sharing
of the {111} lattice planes of the truncated triangular nanocrystals in their best antibacterial
properties because of the high-atom-density {111} facets, enabling more reactivity with the
bacterial cells. Similar effects of sharp edges have been echoed as damaging of bacterial
membranes and killing of S. aureus and E. coli upon direct contact with the extremely sharp
edges of the graphene oxide nanowalls. The nanowalls killed more S. aureus than E. coli,
possessing other outer membrane protection against the damage [169].
Finally, what antibiofilm mechanisms might Ag NP shots or NP shots employ in
general? Unfortunately, researchers have not studied the interactive mechanisms of NPs
with biofilms in much detail. There has also been a controversy between scholars regarding
experimental results. Some observers attributed the antibiofilm effects of NPs to the same
broad antibacterial mechanisms of NPs (i.e., oxidative stress via ROS, the release of metal
ions, and non-oxidative stress). However, this broad concept has been debated by other
studies arguing more intricate interactive mechanisms between NPs and biofilms, taking
into consideration the formation and architecture of biofilms [170]. Gao et al. [171] identi-
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fied the retention of catalytic iron oxide NPs within the biofilm architecture of Streptococcus
mutans. Catalytic NPs activated the co-administered hydrogen peroxide (H2O2) rapidly
under acidic conditions (pH 4.5 to 5.5), mimicking the pH within biofilms and producing in
situ free radicals that concurrently degraded the EPS of biofilms and killed the bacterial cells
embedded within their biofilms. Ghaseminezhad et al. [172] investigated the antibiofilm
effects of Ag NPs and Ag-Fe3O4 nanocomposites against S. aureus biofilms in chronic
wounds. The most striking result of their investigation is that the nanocomposites were
uniformly distributed within the collagen gel matrix containing deeply embedded biofilms,
and S. aureus biofilms were eradicated following the administration of the magnetic field,
pushing the nanocomposites within the collagen matrix. Meanwhile, Ag NPs could not
eradicate S. aureus biofilms, despite releasing more Ag+ ions and producing more ROS
than the nanocomposites. They finally suggested that the antibiofilm mechanisms of their
nanocomposites remain murky. Qin et al. [173] have shed light on the molecular antibiofilm
mechanisms of Ag NPs immobilized in situ on titanium. They attributed the prolonged in-
hibition of Staphylococcus epidermidis (60 days with seven exposure cycles) to the synergetic
(Ag NPs and titanium substrate) inhibition of bacterial adhesion via downregulation of
the expression of biofilm-associated genes (icaA and icaD). These ica genes are virulence
markers and mediate the full slime (EPS) production of S. aureus and S. epidermidis [174].
NPs could inhibit biofilm formation by preventing initial bacterial adhesion by targeting
the cell-surface-associated adhesins [170]. The bacterial surface charge is anionic in both
Gram-positive bacteria, owing to the contained teichoic acids, and Gram-negative bacteria,
owing to the contained lipopolysaccharides in the extra outer membrane [175]. Therefore,
NPs could prevent bacterial–surface adhesion and cell–cell adhesion by electrostatic in-
teractions [170]. For instance, carboxymethyl chitosan/amorphous calcium phosphate
nanocomplexes decreased the adhesion and biofilm formation of S. mutans and Streptococ-
cus gordonii on the enamel surface via electrostatic interactions. The cationic amino groups
in the nanocomplexes neutralized the anionic bacterial surface charge, decreasing bacterial
adhesion to surfaces. The nanocomplexes enhanced the flocculation of particles in the solu-
tion, reducing the cell–cell adhesion [176]. Liao et al. [177] have manufactured theranostic
Au@Ag core–shell NP-decorated silicon nanowires with therapeutic antibacterial proper-
ties against S. aureus and E. coli via physical stress and chemical effects. Bacterial sensing
properties were facilitated in combination with laser-induced breakdown spectroscopy,
quantifying the captured bacteria with a low detection limit. Nanowires offered shear
stress and binding sites for bacterial cells and large-sized extracellular organelles (e.g.,
flagella). Au@Ag NPs offered other binding sites for small-sized extracellular organelles
(e.g., fimbriae) or membrane proteins. Au cores improved the antibacterial activity of Ag
shell atoms. In the same track of preventing bacterial adhesion and biofilm formation, an
adhesive containing Ag NP shots releasing Ag+ ions inhibited the growth of S. mutans
biofilms. Ag+ ions downregulated S. mutans glucosyltransferases (synthesize extracellular
glucans essential for bacterial cell adhesion and biofilm formation) gene expressions (gtfB,
gtfC, and gtfD) [178]. Ag NP shots could also prevent bacterial biofilm formation by the
downregulation of QS-regulated genes, especially those encoding the secretion of virulence
factors as detected in P. aeruginosa biofilms [179]. We believe that further studies that
elaborate on the downregulation by genetic and epigenetic mechanisms in biofilms by NP
shots or ions will need to be undertaken.
4.1.3. Theranostic Electrospun Nanofibers
Electrospinning is an economical, practical, and simple method for the preparation of
nanofibers [180–183]. The biological irony is that all human tissues and organs undergo
deposition in nanofibrous forms (i.e., bone, dentin, collagen, cartilage, and skin) [184].
Electrospun nanofibers have intriguing properties stemming from (i) their nano-scaled
cross-sectional dimensions, such as high surface areas consolidating their functionalization
in a straightforward manner (e.g., drugs, ion-exchangers, nanostructures, and NPs), perme-
ability, and porosity [185–190]. (ii) Their macroscopic length facilitates a well-appreciated
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ease of manipulation [189]. These properties of electrospun nanofibers provide a valid
account in biosensing [191,192]. Biosensors could provide new vistas in wound care via
detecting bacterial wound infections [193]. Electrospun fibers could be a winning strategy
in wound dressing applications, hitting both goals of being physical barriers that prevent
wound-associated infections and acting as a 3D scaffold that replaces the extracellular ma-
trix (ECM) of the skin of the patient [181,183,185,190]. Alteration in the well-orchestrated
skin microbiota composition could be associated with the pathogenesis of inflammatory
skin disease [194]. This is seen in chronic colonized wounds with a prolonged inflam-
matory phase, where bacteria produce inflammatory molecules, attracting inflammatory
cells (i.e., neutrophils and macrophages) into the wound. Activated inflammatory cells
secrete inflammatory cytokines, inducing the increased production of matrix metallopro-
teinases (MMPs). The high levels of MMPs degrade the ECM (a gel-like matrix secreted by
the cells that it encloses and includes polysaccharides, water, and collagen proteins that
elicit the unique elasticity, tensile strength, and compressibility of skin) and consequently
impairs healing [139,195]. S. aureus is a scourge, commonly colonizing or secondarily
infecting the skin of patients with atopic dermatitis [196] and producing delta-toxins that
induce allergic immune and inflammatory skin disease [197]. Dermatologists are more
inclined to prescribe topical corticosteroids and antibiotics for controlling atopic dermatitis.
Phototherapy using ultraviolet (UV; UVA and UVB) is an effective way for controlling
atopic dermatitis, especially with unresponsive patients to topical treatments [196]. In a
study set out to determine the theranostic approach of fibers, Jin et al. [198] used coaxial
electrospinning for preparing core–shell fibers for concurrent imaging and drug delivery.
The shell was formed from Eudragit S100 (a pH-sensitive polymer), and the core was
formed from poly(ethylene oxide) (PEO) loaded with both the magnetic resonance contrast
agent (Gd(III) diethylenetriaminepentaacetate hydrate, Gd(DTPA)) and indomethacin (a
non-steroidal anti-inflammatory drug). The cargoes (Gd(DTPA) and indomethacin) were
not unloaded in the stomach because of the insolubility of the Eudragit shell in acidic
pHs. In contrast, pH increases to alkaline in the intestine’s terminal parts, dissolving the
shell. The exposed PEO core to intestinal fluids would swell and adhere to the intestinal
walls, unloading the Gd(DTPA) and indomethacin for concurrent imaging and treatment
of inflammatory bowel disease, respectively. The pH-responsive drug-loaded electro-
spun nanofibers could further contribute to controlling implant- and wound-associated
infections under the umbrella of nanotheranostics because pH differs in the physiological
and pathological milieus of the human body. For example, the acid–base homeostasis
maintains the physiological pH of arterial blood in the range of 7.36 and 7.44 [199]. Physio-
logically, the skin has acidic pH, preventing bacterial colonization [200], whereas chronic
wounds and highly infected wounds have alkaline pH (above 7.3). The pH could draw
a roadmap, elucidating different phases of the wound healing process that necessitate
different ranges of pH [200,201]. Acidic pH in inflamed tissue potentiates the pathogenic
endocytosis and phagocytosis by transdifferentiated neutrophils [202]. In another endeavor
examining the triggering effect of pH on the drug release from smart electrospun fibers,
Yuan et al. [203] have electrospun an ibuprofen-loaded poly(L-lactide) fibrous scaffold
and shown a quick ibuprofen release from the scaffold at pH 5.0 (preventing excessive
inflammation and promoting muscle wound healing) and a slow-release at pH 7. In an
investigation into the antibiotic cargo of electrospun fibers, Alhusein et al. [204] have
demonstrated an initial burst release of tetracycline (55%) within the first 3 h followed by a
prolonged sustained release (≈80%) after 14 days from a triple (micro/nanofiber)-layered
electrospun matrix. The tetracycline-encapsulated electrospun matrix was composed of a
central layer of poly(ethylene-co-vinyl acetate) sandwiched within the exterior layers of
poly-ε-caprolactone. It eradicated the preformed biofilms of S. aureus for three consecutive
days. Ag-containing polymeric or composite electrospun fibers could be a major area of
interest within fields requiring the prolonged antibacterial actions of Ag NPs, including
implant scaffolds [205,206] and wound dressings [207]. The most sought-after properties
of ideal wound dressings are (i) facilitating the rapid establishment of homeostasis (the
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main process toward wound healing); (ii) providing antibacterial properties (preferably
in a controlled manner); (iii) preventing wound infections; and (iv) being biocompatible,
promoting cell growth. Electrospun nanofibers could elegantly excel wound dressings by
incorporating homeostatic agents (e.g., growth factors) and antibacterial agents. Electro-
spun nanofibers also support homeostasis because of their high surface areas, promoting
cell attachment, and their porosities, allowing gaseous exchange and nutrient supply
and regulating fluid loss [181,182,190,192,208]. Ag is a forerunner antibacterial agent in
electrospun wound dressings because it decreases inflammation at the wound site and
enhances epithelialization [188,209], healing, and the cosmetic appearance of skin [210].
Biodegradable polymeric nanofibers could also be directly electrospun on chronic wounds,
forming dressings that heal wounds and halt the formation of scar tissue [184,209], as
shown in Figure 1.
4.2. Theranostic Antibacterial Star-Shaped Polymers
The synthesis of star-shaped polymers is an increasingly important area in diagno-
sis and polymer therapeutics (e.g., drug delivery, antibacterial, and anti-biofilm agents)
because of their featured structural (physical and chemical) properties, encapsulation
capabilities (because of their 3D structure), functionalities (internal and peripheral), and
heightened stimuli-responsiveness [211]. Star polymers can be classified into two types:
(i) regular or symmetric star polymers that possess identical arm segments; and (ii) mik-
toarm star polymers, which are also defined as asymmetric star polymers or heteroarm
star polymers, possessing diverse chemical structures, topologies, molecular weights, and
functional groups. On the one hand, such heterogeneity of miktoarm star polymers pro-
vides the potential to synthesize novel morphological nanostructures and self-assemblies in
aqueous media, which is promising for biomedical applications (i.e., drug delivery). On the
other hand, the main challenge facing Miktoarm star polymer synthesis is the complicated
process to prepare architectures with various precisely designed arms [211,212]. As far
as antibacterial properties are intended, the much denser functionalities of star polymers
excel in the antibacterial functionalized star polymers over linear polymers’ antibacterial
effects [211].
The combinations of properties of star polymers provide means for their efficient use
for diagnosis in different forms, including fluorescent probes, contrast agents, and in vitro
diagnostics [211]. Qiu et al. [213] have shown the thermo-responsive phase transitions
of star conjugated copolymers (with different poly(2-(dimethylamino)ethyl methacrylate)
(PDMAEMA) chain lengths prepared from the hyperbranched conjugated polymer (HCP))
with adjustable lower critical solution temperature (LCST) according to the pH of the
copolymeric solution. By exceeding the LCST, the arms of PDMAEMA were collapsed,
and the emission of HCP-star-PDMAEMAs was enhanced, detecting E. coli with high
sensitivity. Shen et al. [214] fabricated water-soluble fluorescent Ag nanoclusters (i.e.,
bioimaging labels) from multiarm star poly(acrylic acid) (PAA), which are characterized
by strong binding of the protonated acrylic acid groups with Ag+. The fluorescence of Ag
nanoclusters diminished after 100 min of illumination (i.e., the formation of large Ag NPs).
Sulistio et al. [215] have explored the therapeutic area of star polymers via preparing
(in a one-pot approach using amino acid building blocks, N-carboxyanhydrides), a highly
functionalized water-soluble and degradable core cross-linked star (CCS) polymers. The
therapeutic CCS could release its drug cargo upon degradation. Investigators have recently
examined the multimodal antibacterial therapeutic effects of star-shaped peptide poly-
meric nanoparticles, namely structurally nanoengineered antimicrobial peptide polymers
(SNAPPs). SNAPPS combatted multidrug-resistant superbugs via the physical disruption
of bacterial cell membranes, dysregulation of ion efflux/influx, and induction of apoptotic-
like death [216]. Siedenbiedel et al. [217] identified the antibacterial effects of star-shaped
polymers against S. aureus and E. coli, retaining their antibacterial properties even after
20 water flush treatments. More therapeutic applications of star polymers have also been
reported [218], using star-shaped-brush polymers in electrospinning. The electrospun
Nanomaterials 2021, 11, 82 18 of 36
microfibers (100 mg) killed E. coli (99%) within 2 h of contact. Weng et al. [219] have
shown that furanone containing the star-shaped PAA (as shown in Figure 5) decreased
the viability of Streptococcus mutans, which was unchanged after 30 days of aging in water,
suggesting its potential application as long-lasting antibacterial cement. Bone repair tissue
engineering represents a specific application of biodegradable star polymers due to the
ease of tuning the mechanical properties and degradation time of star polymers. For
example, the covalent cross-links (i.e., the furanone-containing cements with the covalently
bonded antibacterial groups mentioned above [219] and in Figure 5) represent a convenient
approach to developing star polymers retaining an enhanced long-term application [211]
that could reach 30 days in after the furanone-containing cements showed.
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4.3. Ph todynamic Therapy (PDT)
Photodynamic therapy (PDT) plays ti l le in selective bacterial illumination
via selective PS and the efficient treatment of bacterial diseases via the produced ROS [108].
The meaning of ROS refers to reduced oxygen metabolites with strong oxidizing abilities,
deteriorating cells (i.e., oxidizing proteins and lipids and damaging DNA) at high concen-
trations, and serving as signaling molecules (i.e., regulating cell growth, differentiation,
and apoptosis). Well-known examples of ROS are the superoxide anion (O2•−), hydroxyl
radical (OH•), H2O2, and hypochlorous acid (HOCl) [220]. Three main ROS mechanisms
may prove toxic to bacteria (delineated in Figure 6). First, the damage of iron-sulfur (Fe-S)
cluster proteins, where O2− is electrostatically motivated (because of their chemical na-
ture as univalent electron donors), binds the bacterial solvent-exposed Fe-S cluster. ROS
converts them to an unstable oxidized form [221,222] (as displayed in Figure 6). The Fe-S
cluster is inherently recruited as an enzymatic cofactor in several cellular processes, such as
electron transport and enzymatic catalysis and regulation. The cluster binds α,β-dihydroxy
acid substrates, and it is involved in dehydration reactions through catalyzing (activating)
dehydratases [223,224]. The decomposition of the unstable oxidized Fe-S cluster inactivates
the dehydratases [221]. Bacterial switching to fermentation (anaerobic growth) reduces the
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damage of the Fe-S cluster [222,223]. The second ROS mechanism involves the damage
of mononuclear iron enzymes, where O2− and H2O2 inactivate the enzyme family (i.e.,
epimerases, dehydrogenases, deformylases, and deaminases) using the single iron atom
as an enzymatic cofactor. Ultimately, a third mechanism might be associated with the
indirect damage of DNA, where H2O2 produces OH•, damaging the nitrogen-containing
nucleobases and deoxyribose of DNA oxidatively [193]
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iron-sulfur (Fe-S) cluster proteins bound to the α,β-dihydroxy acid substrate after exposure to superoxide (O2−). The cluster
is oxidized, forming hydrogen peroxide (H2 O2), and converted to the unstable oxidized form [4Fe–4S]3+ species [221].
Zheng et al. [225] have taken advantage of the molecular antibiotic mechanism
of MRSA (expressing β-lactamase) and prepared a PS construct (β-lactamase enzyme-
activated PS, β-LEAP) that was cleaved by β-lactamase of MRSA. Following the PS cleav-
age, local ROS were explicitly produced to MRSA upon activation by laser light at 670 nm,
inhibiting the growth of MRSA strains. A direct relationship was observed between the
β-lactamase activity of MRSA and the susceptibility of MRSA to β-LEAP inducing PDT.
Dai et al. [226] have explored the PDT on a bioluminescent MRSA infected mouse wound
using a polyethylenimine-ce6 (PS) and a red light. They have observed that PDT inacti-
vated MRSA efficiently, abrogating the bioluminescence of wounds, and enhanced wound
healing. However, less PDT inactivation of MRSA would be reached in vivo than in vitro
because in vivo, MRSA tends to deeply penetrate tissue, forming biofilms that act as a
barrier, hindering PS’s access, and weakening the penetrated light dose into the deep tissue.
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Jijie et al. [227] have conjugated amine-terminated carbon dots (CDs-NH2, size 6 nm) with
the carboxy group of ampicillin (AMP) via a crosslinker forming amine-functionalized
CDs (CDs-AMP, 41 nm) as a carrier for the immobilization and delivery of AMP cargo.
CDs-AMP demonstrated better antibacterial activities than free AMP against E. coli. This
enhanced antibacterial activity was demonstrated by a decrease (by 40%) in the MIC of
immobilized AMP due to the greater exposure of E. coli cells to larger molecules of the
immobilized AMP that retained its activities even after two weeks of storage (at 4 ◦C in
aqueous solution). CDs-AMP generated ROS (O2•−) under visible light illumination. The
generated O2•− increased with greater exposure time and visible light lamp intensity and
enhanced the antibacterial activity of the conjugate, disrupting the integrity of E. coli mem-
branes. Inspired by the exciting properties of electrospun nanofibers and the antibacterial
efficiencies of PDT (without administering antibiotics), Contreras et al. [228] have recently
combined both systems. They have encapsulated methylene blue (PS) within a biodegrad-
able electrospun poly(ε-caprolactone) (PCL) nanofibrous scaffold for controlling implant
infections. The fibrous scaffold was activated (via visible light) on-demand, reducing the
viability of E. coli (as a model organism for this combined system) that increased with
the time of light exposure (as depicted in Figure 7) due to the production of more ROS. It
would be a fruitful area for further work to investigate the combined antibacterial effects
of these two systems and different nanotheranostic systems, specifically on MRSA. In the
same vein, the fascinating theranostic properties of NPs and nanofibers mentioned above
could be combined with PDT, creating a novel theranostic system, including PDT.
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combined with the bubble-formation phenomenon around the clustered GNPs. This apt 
killing was achieved as increasing the laser energy formed bubbles (life span of 0.1 and 2 
ms and size of 1 to 8 μm) around the hot clustered GDNPs, penetrating bacterial cells 
causing local cell-wall damage and subsequent complete bacterial disintegration. Huang 
et al. [234] prepared iron oxide (Fe3O4)@Au nanoeggs and reported a temperature increase 
in the nanoegg suspension from 23 to about 55 °C after NIR irradiation (808 nm) for 3 min. 
They have further immobilized vancomycin on the surface of nanoeggs. The treated 
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4.4. Photothermal Therapy (PTT)
PTT is a key technology for the treatment of bacterial diseases. However, PTT remains
in a nascent stage (experimentally and only in vitro studies) compared with PDT [108].
Within the PTT technologies, GNPs receive much interest given their elicited optical prop-
erties from their plasmon resonance absorption. Different GNPs (spheres, rods, tubes)
contribute to the shifting of the absorption band into the near-infrared (NIR) wavelength
range and further functionalization [108]. The NIR wavelength range is long (700 to
1700 nm) and is coined as “NIR window” or “optical window” [229,230]. Utilizing this
long NIR light-mediated approach has attracted much interest because it allows deep-tissue
penetration and minimal photodamage to biological tissue [229,231,232]. In contrast, short-
wavelength UV light facilitates both low-tissue penetration and DNA damage, making it
unsuitable for clinical therapy [231], and visible light also facilitates low-tissue penetra-
tion [229]. GNPs also positively promote the localized thermal damaging effects in the
nanometer range surrounding them [108].
In PTT studies using GNPs, Zharov et al. [233] developed a theranostic PTT method for
the selective laser killing of targeted protein A of S. aureus (nanotherapy) by secondary IgG
(Immunoglobulin G)-conjugated 40 nm GNPs. A real-time assessment of the nanotherapy
was exercised using a photothermal microscope (nanodiagnosis) with higher sensitivity
than the transmission technique. Bound S. aureus with conjugated GNPS were irradiated
with laser pulses (420 to 570 nm, 12 ns, 100 pulses), killing bacterial cells aptly combined
with the bubble-formation phenomenon around the clustered GNPs. This apt killing was
achieved as increasing the laser energy formed bubbles (life span of 0.1 and 2 ms and size
of 1 to 8 µm) around the hot clustered GDNPs, penetrating bacterial cells causing local
cell-wall damage and subsequent complete bacterial disintegration. Huang et al. [234]
prepared iron oxide (Fe3O4)@Au nanoeggs and reported a temperature increase in the
nanoegg suspension from 23 to about 55 ◦C after NIR irradiation (808 nm) for 3 min. They
have further immobilized vancomycin on the surface of nanoeggs. The treated MRSA
were entirely covered with the vancomycin-bound nanoeggs and killed (99%) after NIR
irradiation (808 nm, 3 min). The magnetic properties of nanoeggs aggregated the bacterial
cells and contributed to an ace photothermal effect of the vancomycin-bound nanoeggs.
Wang and Irudayaraj [235] assembled magnetic NPs (MNPs, around 15 nm) surrounding
Au nanorods, forming an Fe3O4-Aurod necklace-like probe. They further functionalized
the probe with specific antibodies to E. coli and investigated its simultaneous detection,
separation, and photokilling properties to E. coli within a cocktail of pathogens. The authors
recorded a strong longitudinal plasmon for the probe at 765 nm, which decreased after
30 min incubation with E. coli. This decrease implied the selective binding of several
antibody-bound probes to its targeted much larger E. coli cell (around 1 to 3 µm), even at a
concentration as low as 102 CFU/mL. Following irradiation with NIR light (785 nm) for 15
min, the probe-bound E. coli cells were magnetically separated and cultured, showing no
grown colonies and implying probe absorption to adequate energy after excitation in the
NIR region killing the targeted E. coli.
Similar to GNPs, Fe3O4 MNPs also possess photothermal properties under NIR light
illumination, where Tsai-Jung et al. [236] have found that Fe3O4/alumina core/shell MNPs
specifically targeted and inhibited the cell growth of antibiotic-resistant nosocomial bac-
teria by over 95% within 10 min of illumination. Moreover, the graphene-based PTT was
investigated by Wu et al. [237], preparing MNPs (5 to 8 nm) with reduced graphene oxide
(sheet-like structure) functionalized with glutaraldehyde (GA, cross-linking or capturing
agent), namely MRGOGA. Then, MRGOGA was examined for capturing and killing S.
aureus and E. coli after NIR laser irradiation and in comparison with magnetic reduced
graphene oxide (MRGO) and magnetic carbon nanotubes functionalized with GA (MC-
NGA) (as depicted in Figure 8). They found that PTT was a synergistic interplay of
magnetic properties trapping bacterial cells by an external magnet, reduced graphene
oxide photothermal properties after irradiation, and GA capturing bacterial cells. They
noted no inhibitory effects on bacterial growth for MRGO, showing high bacterial con-
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centrations (measured at an optical density of 600 nm). On the contrary, MRGOGA and
MCNGA inhibited bacterial growth, indicating a sharp drop in the bacterial concentrations
with more enhanced capturing and killing properties for MRGOGA than MCNGA. After
irradiation, MRGOGA rapidly (within 10 min) killed E. coli and S. aureus via increasing
the solution temperature up to ≈50 ◦C, denaturing bacterial enzymes and proteins and
membrane lipids that killed the bacteria. Fan et al. [238] went on to combine the PDT and
PTT nanotheranostic systems in a nanoplatform of star-shaped Fe3O4-Au magnetic core–
plasmonic Au shell NPs (≈70 nm) conjugated to methylene blue (PS)-modified aptamer.
This combined nanoplatform serves for selective detection and separation, fluorescence
imaging, and MRSA destruction within 40 min from binding. Several nanoplatforms are
bound to one MRSA cell because of their smaller size (one order of magnitude) than the
size of MRSA cells. PTT heat destruction of MRSA cells was facilitated by the induction
of plasmonic Au shell by the NIR light (670 nm). The methylene blue developed NIR
fluorescence images after magnetic separation (capture efficiency of 96%). Methylene blue
simultaneously served as a PS facilitating PDT ROS production after light irradiation and a
synergistic agent during PTT, destroying MRSA cells.
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(C). SEM images showing MRGOGA (red arrows) captured S. aureus (yellow arrows) (D) and E. coli (yellow arrows) (E). 
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5.1. Bacterial Challenges
The depressing concept of “community prescribing” antibiotics promotes the trend
of growing antibiotic resistance and remains futile, given that they are often improperly
employed to target viral respiratory infections [239]. The concern of MRSA as a notorious
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skin and soft-tissue infection could also be extended, even rarely, to community-acquired
pneumonia [25]. Culturing methods profiling bacterial communities in chronic wounds
are far from ideal detection methods as they overlook an important pathogen such as
Pseudomonas aeruginosa in chronic wound biofilms [143] and SCVs in patient samples [95].
Moreover, most studies fail to address the relative administration of antibiotics for bacterial
persistence and if persisters could trigger the emergence of resistance [84]. The develop-
ment of effective treatments against biofilms could require adapting targeted treatment
strategies against specific bacterial infections instead of a general approach against all
biofilms [62,91]. Tailoring a universal surface that prevents the adhesion of different bac-
terial pathogens, also under different physiological conditions, could be impossible [57].
In contrast, the majority of biofilm infections, especially implant-associated orthopedic
biofilms, are a repertoire of multispecies bacterial communities, restraining the efficacy of
bacterial species-specific biofilm targeted strategies [4,70].
To date, there is a paradox in the actual antibacterial mechanisms of the action of NPs.
Data from several studies suggest that the ROS produced by active NPs (e.g., Ag NPs) are
the key players of the antibacterial properties. However, a considerable amount of the
literature has refuted any link between the antibacterial properties of NPs and bacterial
metabolism. Several other attempts have been made to attribute the antibacterial properties
of NPs to a sum of those mentioned above three fundamental mechanisms (oxidative
stress, release of metal ions, non-oxidative stress). Therefore, several questions remain to
be answered to unravel the antibacterial mechanisms of different NPs in different media
conditions using unified standard procedures [47]. If products containing nanotheranos-
tics (e.g., wound dressings) released sub-lethal Ag concentrations, Ag-resistance could
be the endpoint [240,241]. Panáček et al. [242] have already demonstrated a bacterial
resistance-like mechanism of E. coli and P. aeruginosa against Ag NPs (28 nm) due to the
production of adhesive flagellum protein (flagellin), aggregating Ag NPs to reach 480 nm.
Strikingly, the emerged resistance-like mechanism did not involve any genetic change.
Ag-resistance genes have also been reported in Salmonella plasmid isolated from a hospital
burn ward [243] and their homologs in E. coli chromosomes [244]. Recently, it was reported
that sub-lethal concentrations of copper oxide (CuO) NPs and copper (Cu2+) ions mediate
the conjugative transfer of plasmid-encoded antibiotic resistance genes from E. coli to
Pseudomonas putida. Horizontal gene transfer was stimulated by ROS (induced by the CuO
NPs and ions), damaging bacterial DNA, activating the SOS response, and encouraging
the conjugative gene transfer [245].
5.2. Nanotheranostics’ Challenges
Speaking on the possible induced toxicities by nanotherapeutics, an ideal agent would
facilitate selective characteristics for the diseased tissue and a therapeutic effect and demon-
strate safety, biodegradability, and lack of immunogenicity [110]. Regarding safety, both
the EMA (the regulatory agency assessing medicines for use in the EU for safeguarding
human and animal health) and the Food and Drug Administration (FDA) provide similar
documentation demonstrating the safety, quality, and efficacy of nanotherapeutics [246].
One of the significant challenges of the theranostic nanomedicine discipline is that most
studies are focused on in vitro investigations (e.g., cell culture studies) rather than in vivo
investigations to pre-clinical and clinical levels, which are more sophisticated [108,246].
Other potential challenges regarding the targeted delivery of the encapsulated drugs
within NPs are (i) achieving successful site-specific drug delivery (lock-and-key concept),
(ii) avoiding the premature release of the drug, and (iii) alleviating in vivo cytotoxic effects.
These potential challenges could not be mimicked in vitro; thus, the in vitro studies are
unsatisfactory [47]. So far, the available in vivo data are limited to either therapeutic or
diagnostic investigation instead of their combination. The development of in silico ap-
proaches envisaging nanotherapeutics’ biological and toxicological interactions requires
comprehensive knowledge on the fate (absorption, distribution, metabolism, and excretion)
of the designed nanotherapeutics in vivo and their association with essential commercial
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features [246]. Possible routes to achieving these challenging approaches will involve (i)
forming multidisciplinary research teams; (ii) training to allow nanotherapeutics’ design
from different perspectives (engineering, biological, toxicological, and clinical); and (iii)
coordination to connect the developed nanotherapeutics in academia with clinical organiza-
tions and industrial stakeholders. Another critical aspect that should be resolved is the lack
of proper funding to financially support the proof-of-concept of the novel nanotherapeutics
designed in academia [47,246]. Furthermore, significant problems of in vivo investigations
of nanotheranostics lie in choosing the animal. A classic example of this problem is that
rats could self-cure infections without antibacterial help, whereas rabbits could suffer
premature death if the challenging bacterial loads were imbalanced. Another well-known
example of this problem is that most bacterial infection studies use young, healthy mice or
dogs. In contrast, human infections often occur in old, sick, or immune-deficient patients
that might also use multiple medications, making no sense to correlate the in vivo ani-
mal findings of antibacterial nanotheranostics to the presaged human findings at clinical
trials [74].
Although electrospun polymeric nanofibers are considered empowered antibacterial
wound dressings, incorporating antibacterial agents (via blending followed by electrospin-
ning or core–shell electrospinning or nozzle-free electrospinning) into the nanofibers and
their commercialization remain incompetent [182,190]. First, the traditional blending fol-
lowed by electrospinning stands as unsatisfactory incorporation of the antibacterial agents
that remain on the polymeric outer shell and exhibit an unfavorable burst release that could
be cytotoxic. Second, in the core–shell electrospinning, the antibacterial agent is encapsu-
lated within a polymeric outer shell that controls its release. However, the high shearing
forces (mechanical stresses) employed at the interface between the core and shell fluids, at
the initiation of electrospinning, could deteriorate the bioactive agents [182,190,247]. Third,
the nozzle-free system simplifies the electrospinning (without maintaining any Taylor
cones). Nevertheless, this system requires intricate maintenance of the high voltage that
could eventually generate sparks [182]. Fourth, a lack of congruence to reproduce iden-
tical scaffolds, especially between diverse research groups, limits the tissue-engineering
applications of the electrospun fibrous mats. [182]. Fifth, even with the ongoing research
for the antibacterial electrospun nanofibers, data about their in vivo safety assessments are
limited [182,183,192]. Therefore, even with the agile features of biopolymeric electrospun
nanofibers that could shine in wound dressing applications, the electrospun fibers’ biocom-
patibility remains a potential issue. This issue is due to the possible presence of impurities
(e.g., residual solvents and linkers) that can elicit immunological responses [182,190].
The biostability and biodegradability of star polymers are essential criteria that should
coincide with their potential applications. The perfect star polymers are stable in maintain-
ing their functions and then sharply biodegrade into non-toxic small molecules that could
be eliminated from the body. The tactics for tailoring the biodegradability of star polymers
are (i) synthesizing biodegradable arms via using biodegradable polypeptides, polymers
(e.g., poly(d,l-lactide) and PCL), and cleavable linkers; (ii) manufacturing biodegradable
cores via biodegradable multi-functional molecules (e.g., cyclodextrin and dextrin) and
cleavable linkers; and (iii) compiling biodegradable arms, cores, and linkers [211]. A po-
tential problem of PDT technology, using a PS construct based on the molecular target of
bacterial resistance, would be the targeted light delivery to the infected site to activate PS to
produce local ROS. However, fiber optics could open vistas for the targeted light delivery
to specific infected sites [225]. A future greater focus on investigating the role of NPs as
imaging contrast agents or specifically combining contrast-enhanced diagnostic imaging
with PDT could produce interesting findings.
6. Our Perspectives: What Solutions?
As hospital settings’ role as a source of nosocomial HA-MRSA infections has been
outlined above, combating MRSA infections could be achieved by limiting unnecessary
hospital visits and performing hand hygiene that is shown to be effective in preventing
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MRSA. Applying measures, such as isolating MRSA infected patients, using protective gear,
reducing inappropriate administration of broad-spectrum antibiotics, and screening MRSA
and eradicating MRSA in colonized patients and healthcare workers should be adequate
measures to curb MRSA infections [37]. We propose a need for legislation preventing the
over-the-counter acquisition of antibiotics, especially in developing countries, to decrease
the pace of emergent resistance. In addition, since NPs have multiple simultaneous antibac-
terial mechanisms, they paralyze the ability of bacteria to mutate and develop resistance
against them genetically. Therefore, we also propose taking the nanotheranostics and their
combinations with antibiotics into consideration for development, safety assessment, and
approval as theranostics against MRSA infections.
Regarding the biofilm dilemma, understanding the mechanism behind how persisters
of S. aureus form would improve our ability to control chronic tolerant infections [88]
instead of removing the untreated infected medical implant or sharp debridement of the
wound. In our words, “we must be intelligent, by acquiring knowledge, to best deal with
the intelligence of bacteria such as forming tolerant persisters.” For example, considering
the dependence of the formation of persisters on (p)ppGpp signaling, using (p)ppGpp
synthesis inhibitors, namely relacin, has shown an elegant reduction of the cell viability
and disruption of biofilms [248]. The acyldepsipeptide antibiotic (ADEP4) activating ClpP
protease has demonstrated efficient killing of persister cells via degrading over 400 proteins,
forcing the self-digestion of cells [249]. Adding glucose to treated S. aureus persisters with
daptomycin has also shown a five-fold increase in the killing of persisters in one hour.
This synergistic glucose–daptomycin effect could be attributed to glucose induction to
specific carbohydrate transport proteins, increasing the susceptibility to daptomycin, or
to glucose stimulating the release or activity of cell-lytic proteins, enhancing the action
of daptomycin [250]. Therefore, taking advantage of such agents (relacin, ADEP4, and
glucose while considering glycemia) to be used as adjuvants with antibiotics or as cargoes in
nanotheranostic systems could provide a brilliant regime for fighting tolerant and resistant
chronic infections.
We believe that electrospun wound dressings could serve as multi-functional smart
dressings, controlling atopic dermatitis. We propose using star polymers with UV-light
responsiveness for electrospinning, where we can benefit from UV-light for both pho-
totherapy and controlled unloading of corticosteroids and antibiotics as an effective topical
treatment of atopic dermatitis. If researchers incorporated NPs mediating the diagnosis
of S. aureus into such electrospun wound dressings controlling atopic dermatitis, then the
successful development of what we call “multifunctional theranostic nanofibers” would be
achieved.
We are coming now to the critical point of biocompatibility and safety of nanotheranos-
tics, which could be comprehensively reviewed in a separate manuscript. A recent review
has highlighted that every distinct form of Ag NP is considered a separate compound
with distinctive physicochemical properties and unique antibacterial and resistance mecha-
nisms [162]. We would like to expand this perspective to infer that every nanotheranostic
system is a unique product that should be thoroughly investigated for biocompatibility
and approved before any commercial antibacterial theranostic application.
7. Conclusions and Future Directions
Here, we have focused on deciphering the problematic S. aureus resistance and
biofilm (lifestyle and myths surrounding it) clinical infections associated with implants
and wounds. Numerous promising antibacterial nanotheranostic systems have been de-
scribed in this comprehensive review. Whereas the literature is beginning to scratch the
surface of the working mechanisms of antibacterial nanotheranostics, this tutorial review
has unraveled the detailed antibacterial and antibiofilm mechanisms of nanotheranostics,
allowing efficient therapy and rapid diagnosis to curb S. aureus infections competently.
We have sought to provide one of the first attempts to thoroughly criticize the reviewed
literature and provide detailed appraisals for combating S. aureus infections. Our “three
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action appraisals” are are follows. (i) First, there are preventive actions that would have
two wings. The first general wing includes avoiding unnecessary hospital visits, hand
hygiene, and legislations against over-the-counter antibiotics, especially in developing
countries. Our second wing of recommended prevention actions includes preventing the
adverse side effects of the NPs from resistance and toxicity. On the one hand, prevent-
ing developed resistance against NPs could be started by establishing standard testing
procedures and breakpoints of bacteria’s susceptibility to NPs, simulating the standard
breakpoints of antibiotic susceptibilities. On the other hand, the toxicity should be avoided
by dealing with every single batch of synthesized NPs as a separate material that should be
thoroughly examined for toxicity in vitro and in vivo, following standard toxicity tests for
NPs. (ii) Theranostic actions include considering NPs combined with antibiotics, glucose,
or antiviral drugs, and “multifunctional theranostic nanofibers” to diagnose and treat S.
aureus infections. We believe in the promising feasible application of these multifunctional
theranostic nanofibers in a short time. This belief is based on the fact that the theranostic
nanofibers would be applied topically, for example, on wound dressings, against the noto-
rious skin pathogen S. aureus. This topical application would decrease the burden of safety
issues for NPs without neglecting the necessary toxicity tests that would remain crucial
before applications. (iii) Scientific actions include scientific collaborations between multi-
disciplinary scientists and the international implementation of these appraisals, especially
establishing standard testing procedures to close the open uncertainty loop surrounding
NPs and their further application as nanotheranostics.
A fruitful area for further work would be the implementation of PDT and PTT sys-
tems in photodynamic therapy and radiotherapy directed for cancer treatment. We also
want to direct the reader’s attention to the following recent, authoritative, and interesting
literature to considerably investigate other antibacterial and anti-biofilm drug delivery
or nanotheranostic systems (e.g., liposomes [251,252], polymeric nanosystems [253,254],
and chitosan-based NPs [255,256]) that constitute importance and, unfortunately, remain
out-of-the scope of the present work. This work’s natural forward movement is to compre-
hensively review the potential anti-coronavirus properties of nanotheranostics as a smart
solution containing the apocalyptic coronavirus disease 2019 (COVID-19) pandemic and
to unravel the MRSA burden on co-infections with COVID-19. This burden needs to be
elucidated, considering the association of resistant MRSA producing Panton-Valentine
leukocidin toxins with pneumonia. Moreover, we are currently finalizing our extended
work on reviewing the safety concerns associated with the administration of antimicrobial
nanotheranostics to unveil the answer to the alarming question: Would nanotheranostics be
safe? We would further conduct empirical research, based on our critical experience, on bio-
compatible antibacterial (anti-S. aureus) and anti-coronavirus nanotheranostics to determine
the clinical efficacy of such systems. Ultimately, we propose the promising employment of
nanotheranostics with their detection and detailed antibacterial and antibiofilm properties
to curb S. aureus and their biofilms in different fields where they are implicated. Such
employment could span across the medical, environmental, and agricultural sectors.
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